Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1987 1
1992 1
1998 2
2000 1
2001 1
2006 1
2007 2
2008 5
2010 1
2012 1
2013 1
2017 1
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Vorapaxar in the secondary prevention of atherothrombotic events.
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators. Morrow DA, et al. N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24. N Engl J Med. 2012. PMID: 22443427 Free article. Clinical Trial.
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group. Merkies ISJ, et al. J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15. J Peripher Nerv Syst. 2019. PMID: 30672091 Free PMC article. Clinical Trial.
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.
Merkies ISJ, Lawo JP, Edelman JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Léger JM; PRIMA trial investigators. Merkies ISJ, et al. J Peripher Nerv Syst. 2017 Jun;22(2):149-152. doi: 10.1111/jns.12204. J Peripher Nerv Syst. 2017. PMID: 28594116 Free PMC article. Clinical Trial. No abstract available.
[Adult form of Pompe disease].
Ziółkowska-Graca B, Kania A, Zwolińska G, Nizankowska-Mogilnicka E. Ziółkowska-Graca B, et al. Among authors: zwolinska g. Pneumonol Alergol Pol. 2008;76(5):396-9. Pneumonol Alergol Pol. 2008. PMID: 19003770 Free article. Polish.
[Neurosarcoidosis and pain].
Borratyńska A, Zwolińska G, Turaj W, Urbanik A, Szczudlik A. Borratyńska A, et al. Among authors: zwolinska g. Neurol Neurochir Pol. 2008 Jan-Feb;42(1):69-74. Neurol Neurochir Pol. 2008. PMID: 18365966 Polish. No abstract available.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
Léger JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Shebl A, Bauhofer A, Zenker O, Merkies IS; PRIMA study investigators. Léger JM, et al. J Peripher Nerv Syst. 2013 Jun;18(2):130-40. doi: 10.1111/jns5.12017. J Peripher Nerv Syst. 2013. PMID: 23781960 Free PMC article. Clinical Trial.
20 results